India Generic Drugs Market Size & Growth Analysis Report, 2020-2026

India generic drugs market is estimated to grow at a CAGR of nearly 9.5% during the forecast period. A significant rise in the incidences of chronic diseases is driving the demand for generic drugs in the country. The National Cancer Registry Programme estimates that there will be 13.9 lakh new cancer incidences reported in India in 2020, which is expected to rise to 15.7 lakh by 2025. This leads to increasing demand for generic drugs that are playing a crucial role in cancer treatment. For instance, in everyday practice, patients with early-stage breast cancer, and children suffering from acute lymphoblastic leukemia are treated and cured with generics. In cancer care, generic drugs are also significantly used in supportive care beyond chemotherapy.

To Request a Sample of our Report on India Generic Drugs Market: https://www.omrglobal.com/request-sample/india-generic-drugs-market

The increasing prevalence of diabetes is also supporting to drive market growth. As per the International Diabetes Federation (IDF), the total cases of diabetes reported in adults in India was nearly 77 million in 2019. This leads to increasing demand for generic medicines for diabetes which include Tolazamide (Tolinase), Acetohexamide, and Glimepiride (Amaryl). Additionally, several generic equivalents of the drug metformin (earlier sold only as Glucophage XR or Glucophage) are now available.

(Get 15% Discount on Buying this Report)
A full Report of India Generic Drugs Market is Available at: https://www.omrglobal.com/industry-reports/india-generic-drugs-market

Scope of the India Generic Drugs Market

Market Coverage
• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Application and Route of Administration
• Competitive Landscape- Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Ltd., Aurobindo Pharma Ltd., and Sun Pharmaceutical Industries Ltd.

Recent Strategic Initiatives in the India Generic Drugs Market
• In July 2020, Cipla declared the launch of its generic version of antiviral drug remdesivir, Cipremi, at $53.3 per 100 mg vial. This makes it among the lowest cost versions for COVID-19 treatment and Cipla is looking to deliver more than 80,000 vials within the first month.
• In July 2020, Mylan launched a generic version of Remdesivir drug, Desrem, in India for treatment of COVID-19 patients. This drug will be available at a price of nearly $64.2 per 100 mg vial as against Hetero’s Covifor at nearly 72.2 per 100 mg vial and Cipla’s Cipremi costing nearly $53.3 per 100 mg vial.
India Generic Drugs Market-Segmentation

By Application
• Cancer
• CVD
• Musculoskeletal Diseases
• Infectious Diseases
• Neurology
• Diabetes
• Others

By Route of Administration
• Oral
• Topical
• Injectable
• Inhaler

Company Profiles
• Aurobindo Pharma Ltd.
• Biocon Ltd.
• Cadila Healthcare Ltd. (CHL)
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals Ltd.
• Lupin Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd

Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/india-generic-drugs-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.